Mark Charbonneau is the Head of Quantitative Biology at Synlogic, Inc., a clinical-stage biopharmaceutical company focused on developing Synthetic Biotic™ medicines which are designed using synthetic biology to genetically reprogram beneficial microbes to treat metabolic and inflammatory diseases and cancer. Dr. Charbonneau’s team develops tools to characterize engineered strain activity in the human gastrointestinal environment, as well as analytical methods to measure products and biomarkers of synthetic pathway activity. Dr. Charbonneau received his B.S. in Microbiology and Molecular Genetics from Michigan State University and his Ph.D. in Computational and Systems Biology from Washington University in St. Louis in the laboratory of Jeffrey I. Gordon, MD. His work has been published in journals including Cell, Nature, and Science.
Head of Quantitative Biology